Corvus Pharmaceuticals, Inc.
CRVS
$3.96
$0.030.76%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 225.43% | 69.88% | -843.62% | 25.24% | 14.31% |
| Total Depreciation and Amortization | 10.00% | -4.76% | 0.00% | -8.70% | -17.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -564.52% | -84.92% | 4,954.24% | -330.13% | -83.67% |
| Change in Net Operating Assets | 110.42% | -1,157.25% | 125.32% | -348.86% | 156.01% |
| Cash from Operations | 2.39% | -33.92% | -15.33% | -6.28% | 0.19% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 170.29% | -56.50% | 77.78% | -249,957.14% | 99.70% |
| Cash from Investing | 169.75% | -56.38% | 77.78% | -249,957.14% | 99.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.50% | 37,116.00% | -99.70% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Financing | -98.50% | 37,116.00% | -99.84% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -192.14% | 139.96% | -237.59% | 243.01% | 31.01% |